Bryant-Li-Bhoj Neurodevelopmental Syndrome 2: Disease-Characteristics Report

Executive summary

Bryant-Li-Bhoj neurodevelopmental syndrome 2 (BLBNS2) is an ultra-rare Mendelian chromatin disorder caused by heterozygous germline variants in H3F3B (current symbol H3-3B), one of two genes encoding the replication-independent histone H3.3 protein. It is the H3-3B-associated subtype of Bryant-Li-Bhoj syndrome (BLBS); the corresponding H3-3A-associated disorder is type 1. The best-supported phenotype comprises developmental delay/intellectual disability, motor and speech delay, tone abnormalities, dysmorphic craniofacial features, abnormal growth, visual impairment, and variably abnormal brain MRI. Some patients develop regression, progressive ataxia, white-matter disease, or cerebral atrophy, but progression is neither universal nor adequately quantified for type 2 alone. Most cases arise from de novo dominant variants, although inherited H3-3B disease has now been documented. No disease-modifying therapy, validated biomarker, formal diagnostic criteria, prevalence estimate, or BLBNS2-specific clinical trial is available.

A central evidence limitation is that most clinical publications pool H3-3A and H3-3B cases. This report therefore labels findings as H3-3B-specific or combined BLBS and does not treat pooled percentages as type-2-specific rates.

Table: This table summarizes the best-supported current knowledge for Bryant-Li-Bhoj neurodevelopmental syndrome 2, emphasizing what is specific to H3F3B versus what is only available from combined BLBS cohorts. It is useful as a compact knowledge-base scaffold and highlights key evidence gaps.

1. Disease information

Definition and identifiers

BLBNS2 is a congenital/pediatric-onset neurodevelopmental disorder—a Mendelian “histonopathy”—caused by germline variation in H3-3B/H3F3B, which encodes histone H3.3. Open Targets maps the disease to MONDO:0030607, OMIM 619721, and Ensembl target ENSG00000132475. The disease became OMIM-classified in 2022. The broader BLBS designation covers both OMIM 619720 and 619721. (layocarris2024expandedphenotypicspectrum pages 3-4, OpenTargets Search: Bryant-Li-Bhoj neurodevelopmental syndrome 2-H3F3B)

Preferred name: Bryant-Li-Bhoj neurodevelopmental syndrome 2.
Synonyms/related labels: BLBNS2; H3F3B-related Bryant-Li-Bhoj syndrome; H3-3B-related neurodevelopmental disorder; histone H3.3-related chromatinopathy, H3-3B subtype. “Bryant-Li-Bhoj syndrome” or “BLBS” is broader and should not be used as an exact synonym when gene-specific precision is required.

No dedicated ICD-10, ICD-11, or MeSH code was identified. In clinical coding, nonspecific codes for intellectual disability, developmental disorder, hypotonia, ataxia, or congenital malformations may therefore be used, but these are not disease identifiers.

Evidence provenance

Knowledge derives primarily from aggregated, investigator-assembled cohorts identified through clinical exome sequencing, Matchmaker Exchange/GeneMatcher-like networks, and literature review—not from population registries or routine EHR-derived epidemiology. The foundational 2020 study included 46 individuals with H3-3A/H3-3B disease, including 13 H3-3B patients carrying 12 unique H3-3B variants. A 2021 cohort added six H3-3B individuals, while the 2024 expanded BLBS analysis reached 96 combined cases. (bryant2020histoneh3.3beyond pages 3-4, okur2021denovovariants pages 2-3, layocarris2024expandedphenotypicspectrum pages 8-9)

2. Etiology, risk, protection, and gene–environment relationships

Causal factor

The primary cause is a heterozygous germline H3-3B variant that alters histone H3.3 sequence, abundance, nucleosome interactions, chaperone binding, or post-translational regulation. Most established variants are missense; stop-loss and transcript-dependent stop-gain consequences have also been reported. The original variants were absent from 138,632 gnomAD controls, consistent with strong rarity and pathogenic constraint. (layocarris2024expandedphenotypicspectrum pages 3-4, bryant2020histoneh3.3beyond pages 3-4)

The original paper’s abstract states: “Germ line mutations in H3F3A and H3F3B cause a previously unidentified neurodevelopmental syndrome.” It further describes “46 patients bearing de novo germline mutations … with progressive neurologic dysfunction and congenital anomalies without malignancies.” This is human cohort evidence, not merely computational inference. Bryant et al., Science Advances, 4 December 2020, PMID 33268356, DOI/URL: https://doi.org/10.1126/sciadv.abc9207. (bryant2020histoneh3.3beyond pages 3-4, bryant2020histoneh3.3beyond pages 2-3)

Risk factors

• Genetic: a pathogenic/likely pathogenic H3-3B allele is the dominant risk factor. Most cases are de novo, but a maternally inherited p.Asn108Ser (p.N108S) allele demonstrates that transmission can occur. Variant position and whether H3-3A or H3-3B is affected appear to influence phenotype more than sex, but robust genotype–phenotype rules have not been established. (layocarris2024expandedphenotypicspectrum pages 3-4, layocarris2024expandedphenotypicspectrum pages 8-9)
• Environmental, lifestyle, infectious, occupational, age, or sex-related risk: none established.
• Family history: usually absent because most variants are de novo; a positive family history is possible in inherited disease or parental mosaicism.
• Modifier genes: none validated. The striking variability among people with the same allele implies additional genetic, epigenetic, developmental, or environmental modifiers, but these remain hypotheses. (layocarris2024expandedphenotypicspectrum pages 3-4)

Protective factors and gene–environment interaction

No protective allele, diet, behavior, exposure, medication, or environmental intervention has been shown to prevent or attenuate BLBNS2. Histone H3.3 lies at the genetics–epigenetics interface, so gene–environment interactions are biologically plausible, but no reproducible interaction has been demonstrated in patients. The 2024 authors explicitly concluded that unmeasured factors likely modify expressivity and highlighted gene–environment research as a future priority. (layocarris2024expandedphenotypicspectrum pages 3-4)

3. Phenotypes

Core clinical spectrum

The quantitative values above must not be interpreted as population prevalence estimates. H3-3B-specific data are available for craniofacial findings and growth trajectory, whereas most other percentages pool both genes. (layocarris2024expandedphenotypicspectrum pages 3-4, bryant2020histoneh3.3beyond pages 3-4, okur2021denovovariants pages 2-3, layocarris2024expandedphenotypicspectrum pages 8-9)

Brain abnormalities reported across BLBS include diminished white matter, hypomyelination, leukodystrophy-like change, cortical dysplasia, leukoencephalopathy, and cerebral/cortical atrophy. Repeat MRI may help distinguish static developmental anomalies from progressive white-matter or volume loss. (bryant2020histoneh3.3beyond pages 3-4, okur2021denovovariants pages 2-3, layocarris2024expandedphenotypicspectrum pages 8-9)

Variability, function, and quality of life

Severity ranges from mild delay to profound disability with inability to attain independent ambulation. In the original combined cohort, 73% attained independent sitting; recurrent variants could nevertheless produce markedly different milestones, regression, seizures, and tone findings. Such variability argues against deterministic prognosis based only on variant identity. (bryant2020histoneh3.3beyond pages 3-4, bryant2020histoneh3.3beyond pages 2-3)

No BLBNS2-specific EQ-5D, SF-36, PROMIS, caregiver-burden, or other quality-of-life study was found. Expected effects include impaired communication, mobility, feeding, education, self-care, and independent living, but quantitative utility weights are unavailable.

Seizures, hearing abnormalities, cardiac/circulatory findings, genitourinary findings, and endocrine abnormalities occur in some reports, but a 2025 deep-phenotyping analysis did not support them as consistently associated BLBS features. They should be recorded and treated when present without being considered obligatory manifestations. (lubin2025couplingdeepphenotypic pages 9-11)

4. Genetic and molecular information

Gene and variant classes

Causal gene: H3-3B/H3F3B, encoding histone H3.3B. The original 46-person study found 13 H3-3B cases and 12 unique H3-3B variants; a recurrent H3-3B allele was p.Pro121Arg. More recent examples include p.Gly34Arg, p.Gly34Val, p.Asn108Ser, p.Val117Val/p.Ser147Ter (transcript-dependent consequence), and a two-base stop-loss deletion reported as p.137Cext9 or p.Cys136*ext9, depending on transcript/notation. (layocarris2024expandedphenotypicspectrum pages 3-4, bryant2020histoneh3.3beyond pages 3-4, okur2021denovovariants pages 2-3, layocarris2024expandedphenotypicspectrum pages 8-9)

Variant classes: predominantly missense, but synonymous variants with noncanonical-transcript stop consequences and stop-loss/extension variants establish a broader allelic spectrum. Most are germline and heterozygous. No evidence supports a somatic mosaic tumor mechanism as the usual cause of BLBNS2.

Classification: pathogenicity requires ACMG/AMP assessment integrating de novo occurrence, population absence, phenotype consistency, recurrence, structural location, and functional data. A variant should not be labeled pathogenic solely because it alters H3-3B; variant-level ClinVar assertions may differ and require current review.

Population frequency: established cohort variants were absent from 138,632 gnomAD controls. Exact per-variant gnomAD v4, TOPMed, and ancestry-stratified frequencies were not available in the retrieved evidence. (bryant2020histoneh3.3beyond pages 3-4)

Functional effects

Variant consequences are heterogeneous rather than a single simple null mechanism. Structural modeling of 37 variants at 25 H3.3 residues predicted disruption of DNA contacts, histone-octamer stability, intramolecular contacts, or binding to histone chaperones and epigenetic regulators. Experimental constructs showed reduced abundance for p.Arg129His, p.Met121Ile, and p.Ile52Asn, increased abundance for p.Arg41Cys, and approximately wild-type abundance for an elongated stop-loss protein. p.Arg129His increased interaction with the chaperone DAXX in one assay. These observations support altered-function, stability, and interaction mechanisms rather than uniform haploinsufficiency. (bryant2020histoneh3.3beyond pages 3-4, okur2021denovovariants pages 2-3)

No validated modifier gene, disease-specific DNA-methylation episignature, large chromosomal rearrangement, recurrent CNV, or parent-of-origin effect is established. Conventional aneuploidy, translocation, and repeat-expansion mechanisms are not characteristic.

5. Environmental information

No toxin, radiation exposure, pollutant, occupation, smoking, alcohol use, diet, physical activity pattern, infection, or microbiome state has been shown to cause or trigger BLBNS2. It is not infectious or contagious. Environmental history remains clinically useful for excluding phenocopies and managing general health, but it does not presently alter molecular diagnosis.

6. Mechanism and pathophysiology

Proposed causal chain

1. Upstream trigger: a heterozygous germline H3-3B sequence variant produces an altered H3.3 molecule.
2. Nucleosome-level dysfunction: the mutant histone changes DNA contacts, nucleosome stability, or interaction with chaperones such as DAXX/UBN1 and chromatin readers.
3. Epigenetic disturbance: post-translational modifications are altered locally in cis on mutant H3.3 rather than globally on all histones, distinguishing these germline alleles from canonical somatic “oncohistone” mechanisms.
4. Transcription/cell-cycle disturbance: patient-cell RNA sequencing shows upregulation of mitosis and cell-division programs; fibroblasts demonstrate increased proliferation and altered S/G2 distribution without a major viability defect.
5. Developmental tissue effects: disturbed chromatin regulation affects neural development, glial/neural-crest derivatives, craniofacial development, and potentially white-matter maintenance.
6. Clinical outcome: developmental delay, intellectual disability, tone and gait abnormalities, dysmorphism, growth disturbance, and—in a subset—progressive neurologic dysfunction or atrophy. (bryant2020histoneh3.3beyond pages 3-4, bryant2020histoneh3.3beyond pages 7-8)

In five patient fibroblast lines, including lines with H3-3B p.Gly34Val, p.Val117Val, and p.Ser146Ter-related variants, proliferation was increased relative to six controls, with significant S- and G2-phase changes. This is direct patient-derived in-vitro evidence but does not prove that excess proliferation is the sole neuronal disease mechanism. (bryant2020histoneh3.3beyond pages 7-8)

The foundational abstract reports: “Patient histone posttranslational modifications analysis revealed notably aberrant local PTM patterns” and “RNA sequencing on patient cells demonstrated up-regulated gene expression related to mitosis and cell division.” It concludes that germline and cancer-associated mutations are mechanistically distinct but may converge on proliferation control. (bryant2020histoneh3.3beyond pages 7-8)

Relevant ontology suggestions

• GO biological process: chromatin organization; nucleosome assembly; regulation of transcription by chromatin organization; histone modification; mitotic cell cycle; regulation of cell proliferation; nervous-system development; glial-cell development; neural-crest-cell development.
• GO cellular component: nucleosome; chromatin; nucleus; chromosome.
• CL cell types: neuron; glial cell; neural crest cell; oligodendrocyte lineage cell; fibroblast for patient-cell assays.
• Molecular profiling: disease-relevant bulk RNA sequencing, histone PTM proteomics, interaction proteomics, and cell-cycle profiling exist. No validated patient single-cell, spatial transcriptomic, metabolomic, lipidomic, or integrated clinical multi-omic signature was identified.
• Immune/metabolic/tissue-injury mechanisms: no primary immunodeficiency, autoimmunity, enzyme deficiency, mitochondrial metabolic defect, fibrosis, ischemia, or inflammatory tissue-injury pathway is established.

7. Anatomical structures affected

Primary system: central nervous system, particularly brain development and white matter. Suggested terms include UBERON:brain, cerebral cortex, cerebral white matter, cerebellum, and central nervous system. MRI abnormalities are generally bilateral/diffuse rather than a consistently lateralized lesion. (bryant2020histoneh3.3beyond pages 3-4, okur2021denovovariants pages 2-3)

Secondary structures: craniofacial skeleton and soft tissues, eyes/visual system, skeletal/extremity structures, and gastrointestinal/feeding systems. Cardiac, endocrine, auditory, and genitourinary abnormalities may occur but are not firmly established as core type-2 manifestations. (lubin2025couplingdeepphenotypic pages 9-11, okur2021denovovariants pages 2-3)

Cellular/subcellular localization: neurons and glia are clinically implicated; neural-crest derivatives are supported by zebrafish data. The fundamental subcellular site is nuclear chromatin/nucleosomes rather than mitochondria, lysosome, or endoplasmic reticulum. Suggested GO cellular-component terms are nucleus, chromatin, chromosome, and nucleosome.

8. Temporal development and natural history

BLBNS2 is usually congenital or early pediatric in onset, although the molecular lesion is present from conception. Developmental delay, hypotonia, feeding/growth concerns, or dysmorphism commonly become evident in infancy or early childhood. The course is lifelong and highly variable.

The original mixed cohort, aged 2 months to 32 years, documented neurologic degeneration in 9/46 (21%), cortical atrophy in 26%, and three deaths. These figures demonstrate that progression and mortality can occur but do not establish H3-3B-specific survival risks. Later work emphasizes a mixed neurodevelopmental–neurodegenerative spectrum, including progressive gait ataxia, rather than universal degeneration. (bryant2020histoneh3.3beyond pages 3-4, layocarris2024expandedphenotypicspectrum pages 8-9)

There are no validated stages, median progression rate, remission pattern, or critical therapeutic window. Developmental surveillance and early habilitation are rational because infancy and early childhood are periods of high neuroplasticity, but no study has quantified a disease-specific window of reversibility.

9. Inheritance and population

Inheritance

The best model is autosomal dominant, usually due to a de novo heterozygous germline allele. One maternally inherited p.Asn108Ser variant expands the spectrum beyond strictly de novo disease. (bryant2020histoneh3.3beyond pages 3-4, layocarris2024expandedphenotypicspectrum pages 8-9)

Penetrance is unknown; expressivity is clearly variable, including among individuals with the same allele. No anticipation, founder effect, consanguinity association, carrier frequency, or population-specific enrichment has been established. Parental germline or low-level somatic mosaicism has not been quantified and remains relevant to recurrence counseling.

Epidemiology

No incidence, prevalence, sex ratio, ethnic predisposition, or geographic distribution can be estimated reliably. Published cases span multiple countries and ancestries, supporting worldwide occurrence rather than endemicity. Case discovery depends heavily on access to exome/genome sequencing. The original combined cohort contained 27 males and 19 females, but this ascertainment ratio is not evidence of sex-biased risk. (bryant2020histoneh3.3beyond pages 3-4)

10. Diagnostics

Recommended approach

1. Clinical recognition: unexplained developmental/intellectual disability with tone abnormality, gait disorder, growth disturbance, dysmorphism, visual problems, or abnormal brain MRI.
2. First-line molecular testing: trio whole-exome or whole-genome sequencing is preferred for a genetically heterogeneous neurodevelopmental presentation. A comprehensive neurodevelopmental/chromatinopathy panel should include H3-3B/H3F3B and H3-3A/H3F3A.
3. Variant confirmation: orthogonal confirmation as appropriate, parental testing, transcript-aware HGVS annotation, population-database review, and ACMG/AMP classification.
4. Phenotypic assessment: developmental evaluation; neurologic examination; growth and feeding assessment; ophthalmology; hearing testing; and brain MRI. EEG is indicated for suspected seizures or episodic movements, not universally as a diagnostic biomarker.
5. Longitudinal evaluation: repeat neurologic, gait, vision, growth, and developmental assessment; repeat MRI when progression, regression, ataxia, or new focal findings emerge. (okur2021denovovariants pages 2-3, layocarris2024expandedphenotypicspectrum pages 8-9)

The 2021 abstract states that detailed phenotyping of H3-3A and H3-3B cases showed “global developmental delay, short stature, failure to thrive, dysmorphic facial features, structural brain abnormalities, hypotonia, and visual impairment.” Okur et al., npj Genomic Medicine, December 2021, PMID 34876591, DOI/URL: https://doi.org/10.1038/s41525-021-00268-8. (okur2021denovovariants pages 2-3)

Role of other tests

• CMA: useful when first-tier testing for developmental disability or to find an alternative CNV, but cannot reliably detect most causative H3-3B single-nucleotide variants.
• Karyotype/FISH: not routinely informative unless another chromosomal diagnosis is suspected.
• Single-gene sequencing: reasonable for a highly suggestive phenotype or familial variant, but exome/genome testing usually offers better differential coverage.
• RNA sequencing: potentially useful for transcript-dependent splice/stop consequences or uncertain variants, but not a validated routine assay.
• Methylation/proteomics/metabolomics: no clinically validated BLBNS2 signature.
• Mitochondrial DNA and repeat-expansion tests: not disease-specific; use only when the differential warrants them.

Differential diagnosis

Important alternatives include H3-3A-related BLBNS1, other germline histonopathies/chromatinopathies, leukodystrophies and hypomyelinating disorders, cerebral-palsy phenocopies, mitochondrial disease, congenital disorders of glycosylation, syndromic intellectual disability with growth failure, and genetic ataxia or movement disorders. Leukodystrophy overlap is especially relevant when progressive gait ataxia or white-matter abnormalities dominate. (okur2021denovovariants pages 2-3, layocarris2024expandedphenotypicspectrum pages 8-9)

There are no standardized clinical diagnostic criteria, prenatal ultrasound signature, newborn biochemical screen, or population screening program.

11. Outcome and prognosis

Prognosis is variable. Developmental impairment is generally lifelong; functional outcomes range from delayed but achieved milestones to severe dependence. Regression, progressive ataxia, and cerebral atrophy occur in a subset. Three deaths were reported in the original 46-person combined cohort, but causes, age-specific mortality, and H3-3B-specific contribution are insufficient to estimate life expectancy or survival curves. (bryant2020histoneh3.3beyond pages 3-4)

No validated prognostic biomarker exists. Variant location and affected paralog may influence particular phenotypes, but neither currently supports an individual outcome calculator. Sex was less explanatory than gene and protein position in the expanded analysis, while substantial residual variability remained. (layocarris2024expandedphenotypicspectrum pages 3-4)

Potential complications include feeding/growth failure, immobility, contracture or orthopedic problems, communication impairment, falls from ataxia, visual disability, seizures in a minority, and caregiver burden. No formal recovery rate or treatment-response rate has been published.

12. Treatment and current applications

Current clinical implementation

There is no FDA/EMA-approved disease-modifying or genotype-targeted treatment. Care is multidisciplinary and phenotype-directed:

• developmental pediatrics and neurology follow-up;
• early physical, occupational, speech/language, communication, and feeding therapy;
• nutritional support and swallowing assessment when indicated;
• mobility aids, orthotics, and orthopedic management for gait or skeletal problems;
• standard antiseizure medication when epilepsy is documented;
• ophthalmologic correction or low-vision support;
• audiology and endocrine/cardiac evaluation when clinically indicated;
• educational planning, augmentative communication, psychosocial support, respite care, and genetic counseling.

Suggested NCIT intervention concepts include Supportive Care, Physical Therapy, Occupational Therapy, Speech Therapy, Nutritional Support, Genetic Counseling, and Anticonvulsant Therapy. These are ontology suggestions, not BLBNS2-specific efficacy claims.

No BLBNS2 interventional clinical trial was identified. Trials retrieved through broad H3F3A/H3F3B searches concerned somatic H3-mutant gliomas and must not be extrapolated to germline BLBNS2. Gene replacement, CRISPR editing, allele-selective silencing, ASOs, cell therapy, immunotherapy, and chromatin-targeted drugs remain preclinical concepts without demonstrated patient benefit.

13. Prevention

Primary prevention: no lifestyle, vaccine, environmental, or pharmacologic intervention prevents a de novo germline H3-3B variant.

Secondary prevention/early detection: prompt genomic testing can shorten the diagnostic odyssey and initiate developmental, feeding, vision, mobility, and educational support. There is no newborn screening assay or evidence supporting population screening.

Tertiary prevention: monitor growth, swallowing, mobility, contractures, vision, neurologic regression, and seizures to reduce avoidable complications.

Reproductive options: genetic counseling; parental testing; assessment for parental mosaicism when technically feasible; prenatal diagnosis by CVS/amniocentesis; or preimplantation genetic testing once a familial pathogenic variant is established. For an affected heterozygous individual, theoretical transmission risk is 50% per pregnancy, subject to penetrance and reproductive fitness. After an apparently de novo case, recurrence risk is low but not zero because germline mosaicism cannot be excluded. No disease-specific empirical mosaicism estimate is available.

14. Other species and natural disease

No naturally occurring veterinary counterpart, affected breed, zoonotic reservoir, or cross-species transmission phenomenon was identified. BLBNS2 is genetic and noncommunicable. H3.3 biology is evolutionarily conserved, making animal orthologs useful experimentally, but conservation does not establish spontaneous animal disease.

Relevant experimental taxa include Homo sapiens (NCBI Taxon 9606), Danio rerio (zebrafish; Taxon 7955), and potentially Mus musculus (mouse; Taxon 10090). Exact ortholog NCBI Gene identifiers should be verified directly before database ingestion.

15. Model organisms and experimental systems

Patient-derived cells

Patient fibroblasts are the strongest disease-proximal in-vitro model. They demonstrate variant-specific PTM changes, altered transcriptional programs, increased proliferation, and S/G2 cell-cycle changes. Their limitation is that fibroblasts do not reproduce neuronal/glial maturation, circuitry, myelination, or neurodegeneration. (bryant2020histoneh3.3beyond pages 7-8)

Zebrafish

H3.3 perturbation in zebrafish produced craniofacial anomalies and defects in Foxd3-derived glia and other neural-crest derivatives, providing organism-level support for craniofacial and glial mechanisms. The original abstract states: “A zebrafish model showed craniofacial anomalies and a defect in Foxd3-derived glia.” However, this is not a fully validated H3-3B-variant-specific model of every human phenotype. (bryant2020histoneh3.3beyond pages 7-8)

Other models and applications

Structural modeling and transfected variant constructs have been used to examine nucleosome interfaces, protein abundance, and chaperone binding. No dedicated mammalian knock-in model, patient iPSC-derived neural model, cerebral organoid, or H3-3B-specific longitudinal vertebrate model was identified in the retrieved evidence. Priority applications include testing allele-specific mechanisms, defining neuronal versus oligodendroglial vulnerability, studying myelination and regression, and evaluating allele-selective therapeutic strategies.

Recent developments and expert interpretation

The major 2024 advance was expansion from an initially narrow “de novo missense neurodegenerative syndrome” to a 96-person, phenotypically heterogeneous neurodevelopmental–neurodegenerative spectrum encompassing missense, synonymous/transcript-dependent, stop-loss, and inherited alleles. The authors found no conclusive simple genotype–phenotype correlation; gene and protein location appeared more informative than sex, but substantial variability remained. Layo-Carris et al., European Journal of Human Genetics 32:928–937, published April 2024, DOI/URL: https://doi.org/10.1038/s41431-024-01610-1. (layocarris2024expandedphenotypicspectrum pages 3-4, layocarris2024expandedphenotypicspectrum pages 8-9)

The paper’s abstract summarizes the current expert position: “phenotypic heterogeneity was present even amongst individuals harboring the same variant” and “additional factors may play a role in modifying the phenotypes.” This supports cautious individualized prognosis and continued longitudinal study rather than rigid variant-based prediction. (layocarris2024expandedphenotypicspectrum pages 3-4)

A 2025 deep-phenotyping study of 192 individuals with germline histonopathies further reinforced developmental delay/intellectual disability, motor and speech delay, MRI abnormalities, hypotonia, vision abnormalities, head-size abnormalities, and skeletal findings as central BLBS domains, while finding weaker support for seizures and several non-neurologic systems as consistent syndrome associations. It also reported an adult H3-3B p.Lys23Arg carrier with an atypical pulmonary carcinoid at age 33; this isolated observation is insufficient to establish cancer predisposition or justify routine tumor surveillance. Lubin et al., Human Genetics and Genomics Advances 6:100440, July 2025, https://doi.org/10.1016/j.xhgg.2025.100440. (lubin2025couplingdeepphenotypic pages 9-11)

Principal knowledge gaps

1. H3-3B-specific phenotype denominators and longitudinal natural history.
2. Incidence, prevalence, penetrance, sex ratio, mortality, and life expectancy.
3. Systematic parental-mosaicism and reproductive-risk data.
4. Variant-level functional classification and reproducible genotype–phenotype relationships.
5. Neuron-, oligodendrocyte-, and brain-organoid models specific to H3-3B alleles.
6. Validated epigenomic, transcriptomic, imaging, or fluid biomarkers.
7. Controlled evidence for surveillance and supportive interventions.
8. Disease-modifying therapies and BLBNS2-specific clinical trials.

Accordingly, BLBNS2 should currently be represented in a knowledge base as a de novo-dominant, variably expressive H3-3B histonopathy with developmental and possible progressive neurologic manifestations, while marking most frequency, prognosis, and treatment fields as incomplete rather than absent.

References

1. (layocarris2024expandedphenotypicspectrum pages 3-4): Dana E. Layo-Carris, Emily E. Lubin, Annabel K. Sangree, Kelly J. Clark, Emily L. Durham, Elizabeth M. Gonzalez, Sarina Smith, Rajesh Angireddy, Xiao Min Wang, Erin Weiss, Annick Toutain, Roberto Mendoza-Londono, Lucie Dupuis, Nadirah Damseh, Danita Velasco, Irene Valenzuela, Marta Codina-Solà, Catherine Ziats, Jaclyn Have, Katie Clarkson, Dora Steel, Manju Kurian, Katy Barwick, Diana Carrasco, Aditi I. Dagli, M. J. M. Nowaczyk, Miroslava Hančárová, Šárka Bendová, Darina Prchalova, Zdeněk Sedláček, Alica Baxová, Catherine Bearce Nowak, Jessica Douglas, Wendy K. Chung, Nicola Longo, Konrad Platzer, Chiara Klöckner, Luisa Averdunk, Dagmar Wieczorek, Ilona Krey, Christiane Zweier, Andre Reis, Tugce Balci, Marleen Simon, Hester Y. Kroes, Antje Wiesener, Georgia Vasileiou, Nikolaos M. Marinakis, Danai Veltra, Christalena Sofocleous, Konstantina Kosma, Joanne Traeger Synodinos, Konstantinos A. Voudris, Marie-Laure Vuillaume, Paul Gueguen, Nicolas Derive, Estelle Colin, Clarisse Battault, Billie Au, Martin Delatycki, Mathew Wallis, Lyndon Gallacher, Fatma Majdoub, Noor Smal, Sarah Weckhuysen, An-Sofie Schoonjans, R. Frank Kooy, Marije Meuwissen, Benjamin T. Cocanougher, Kathryn Taylor, Carolyn E. Pizoli, Marie T. McDonald, Philip James, Elizabeth R. Roeder, Rebecca Littlejohn, Nicholas A. Borja, Willa Thorson, Kristine King, Radka Stoeva, Manon Suerink, Esther Nibbeling, Stephanie Baskin, Gwenaël L. E. Guyader, Julie Kaplan, Candace Muss, Deanna Alexis Carere, Elizabeth J. K. Bhoj, and Laura M. Bryant. Expanded phenotypic spectrum of neurodevelopmental and neurodegenerative disorder bryant-li-bhoj syndrome with 38 additional individuals. European Journal of Human Genetics, 32:928-937, Apr 2024. URL: https://doi.org/10.1038/s41431-024-01610-1, doi:10.1038/s41431-024-01610-1. This article has 12 citations and is from a domain leading peer-reviewed journal.

2. (OpenTargets Search: Bryant-Li-Bhoj neurodevelopmental syndrome 2-H3F3B): Open Targets Query (Bryant-Li-Bhoj neurodevelopmental syndrome 2-H3F3B, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

3. (okur2021denovovariants pages 2-3): Volkan Okur, Zefu Chen, Liesbeth Vossaert, Sandra Peacock, Jill Rosenfeld, Lina Zhao, Haowei Du, Emily Calamaro, Amanda Gerard, Sen Zhao, Jill Kelsay, Ashley Lahr, Chloe Mighton, Hillary M. Porter, Amy Siemon, Josh Silver, Shayna Svihovec, Chin-To Fong, Christina L. Grant, Jordan Lerner-Ellis, Kandamurugu Manickam, Suneeta Madan-Khetarpal, Shawn E. McCandless, Chantal F. Morel, G. Bradley Schaefer, Elizabeth M. Berry-Kravis, Ryan Gates, Natalia Gomez-Ospina, Guixing Qiu, Terry Jianguo Zhang, Zhihong Wu, Linyan Meng, Pengfei Liu, Daryl A. Scott, James R. Lupski, Christine M. Eng, Nan Wu, and Bo Yuan. De novo variants in h3-3a and h3-3b are associated with neurodevelopmental delay, dysmorphic features, and structural brain abnormalities. npj Genomic Medicine, Dec 2021. URL: https://doi.org/10.1038/s41525-021-00268-8, doi:10.1038/s41525-021-00268-8. This article has 32 citations and is from a peer-reviewed journal.

4. (bryant2020histoneh3.3beyond pages 3-4): Laura Bryant, Dong Li, Samuel G. Cox, Dylan Marchione, Evan F. Joiner, Khadija Wilson, Kevin Janssen, Pearl Lee, Michael E. March, Divya Nair, Elliott Sherr, Brieana Fregeau, Klaas J. Wierenga, Alexandrea Wadley, Grazia M. S. Mancini, Nina Powell-Hamilton, Jiddeke van de Kamp, Theresa Grebe, John Dean, Alison Ross, Heather P. Crawford, Zoe Powis, Megan T. Cho, Marcia C. Willing, Linda Manwaring, Rachel Schot, Caroline Nava, Alexandra Afenjar, Davor Lessel, Matias Wagner, Thomas Klopstock, Juliane Winkelmann, Claudia B. Catarino, Kyle Retterer, Jane L. Schuette, Jeffrey W. Innis, Amy Pizzino, Sabine Lüttgen, Jonas Denecke, Tim M. Strom, Kristin G. Monaghan, Zuo-Fei Yuan, Holly Dubbs, Renee Bend, Jennifer A. Lee, Michael J. Lyons, Julia Hoefele, Roman Günthner, Heiko Reutter, Boris Keren, Kelly Radtke, Omar Sherbini, Cameron Mrokse, Katherine L. Helbig, Sylvie Odent, Benjamin Cogne, Sandra Mercier, Stephane Bezieau, Thomas Besnard, Sebastien Kury, Richard Redon, Karit Reinson, Monica H. Wojcik, Katrin Õunap, Pilvi Ilves, A. Micheil Innes, Kristin D. Kernohan, Gregory Costain, M. Stephen Meyn, David Chitayat, Elaine Zackai, Anna Lehman, Hilary Kitson, Martin G. Martin, Julian A. Martinez-Agosto, Stan F. Nelson, Christina G. S. Palmer, Jeanette C. Papp, Neil H. Parker, Janet S. Sinsheimer, Eric Vilain, Jijun Wan, Amanda J. Yoon, Allison Zheng, Elise Brimble, Giovanni Battista Ferrero, Francesca Clementina Radio, Diana Carli, Sabina Barresi, Alfredo Brusco, Marco Tartaglia, Jennifer Muncy Thomas, Luis Umana, Marjan M. Weiss, Garrett Gotway, K. E. Stuurman, Michelle L. Thompson, Kirsty McWalter, Constance T. R. M. Stumpel, Servi J. C. Stevens, Alexander P. A. Stegmann, Kristian Tveten, Arve Vøllo, Trine Prescott, Christina Fagerberg, Lone Walentin Laulund, Martin J. Larsen, Melissa Byler, Robert Roger Lebel, Anna C. Hurst, Joy Dean, Samantha A. Schrier Vergano, Jennifer Norman, Saadet Mercimek-Andrews, Juanita Neira, Margot I. Van Allen, Nicola Longo, Elizabeth Sellars, Raymond J. Louie, Sara S. Cathey, Elly Brokamp, Delphine Heron, Molly Snyder, Adeline Vanderver, Celeste Simon, Xavier de la Cruz, Natália Padilla, J. Gage Crump, Wendy Chung, Benjamin Garcia, Hakon H. Hakonarson, and Elizabeth J. Bhoj. Histone h3.3 beyond cancer: germline mutations in histone 3 family 3a and 3b cause a previously unidentified neurodegenerative disorder in 46 patients. Science Advances, Dec 2020. URL: https://doi.org/10.1126/sciadv.abc9207, doi:10.1126/sciadv.abc9207. This article has 92 citations and is from a highest quality peer-reviewed journal.

5. (layocarris2024expandedphenotypicspectrum pages 8-9): Dana E. Layo-Carris, Emily E. Lubin, Annabel K. Sangree, Kelly J. Clark, Emily L. Durham, Elizabeth M. Gonzalez, Sarina Smith, Rajesh Angireddy, Xiao Min Wang, Erin Weiss, Annick Toutain, Roberto Mendoza-Londono, Lucie Dupuis, Nadirah Damseh, Danita Velasco, Irene Valenzuela, Marta Codina-Solà, Catherine Ziats, Jaclyn Have, Katie Clarkson, Dora Steel, Manju Kurian, Katy Barwick, Diana Carrasco, Aditi I. Dagli, M. J. M. Nowaczyk, Miroslava Hančárová, Šárka Bendová, Darina Prchalova, Zdeněk Sedláček, Alica Baxová, Catherine Bearce Nowak, Jessica Douglas, Wendy K. Chung, Nicola Longo, Konrad Platzer, Chiara Klöckner, Luisa Averdunk, Dagmar Wieczorek, Ilona Krey, Christiane Zweier, Andre Reis, Tugce Balci, Marleen Simon, Hester Y. Kroes, Antje Wiesener, Georgia Vasileiou, Nikolaos M. Marinakis, Danai Veltra, Christalena Sofocleous, Konstantina Kosma, Joanne Traeger Synodinos, Konstantinos A. Voudris, Marie-Laure Vuillaume, Paul Gueguen, Nicolas Derive, Estelle Colin, Clarisse Battault, Billie Au, Martin Delatycki, Mathew Wallis, Lyndon Gallacher, Fatma Majdoub, Noor Smal, Sarah Weckhuysen, An-Sofie Schoonjans, R. Frank Kooy, Marije Meuwissen, Benjamin T. Cocanougher, Kathryn Taylor, Carolyn E. Pizoli, Marie T. McDonald, Philip James, Elizabeth R. Roeder, Rebecca Littlejohn, Nicholas A. Borja, Willa Thorson, Kristine King, Radka Stoeva, Manon Suerink, Esther Nibbeling, Stephanie Baskin, Gwenaël L. E. Guyader, Julie Kaplan, Candace Muss, Deanna Alexis Carere, Elizabeth J. K. Bhoj, and Laura M. Bryant. Expanded phenotypic spectrum of neurodevelopmental and neurodegenerative disorder bryant-li-bhoj syndrome with 38 additional individuals. European Journal of Human Genetics, 32:928-937, Apr 2024. URL: https://doi.org/10.1038/s41431-024-01610-1, doi:10.1038/s41431-024-01610-1. This article has 12 citations and is from a domain leading peer-reviewed journal.

6. (lubin2025couplingdeepphenotypic pages 9-11): Emily E. Lubin, Elizabeth M. Gonzalez, Annabel K. Sangree, Emily L. Durham, Hannah Klinkhammer, Jing-Mei Li, Sarina M. Smith, Dana E. Layo-Carris, Kelly J. Clark, Ashley J. Melendez-Perez, Xiao Min Wang, Rajesh Angireddy, Erin E. Weiss, Tahsin Stefan Barakat, Sandra Mercier, Benjamin Cogné, Saskia Koene, Yvonne Hilhorst-Hofstee, Malgorzata Rydzanicz, Rafal Ploski, María de los Ángeles Gómez Cano, María Palomares-Bralo, Tania Barragán Arévalo, Tiong Yang Tan, Lyndon Gallacher, Suzanne P. MacFarland, Rebecca C. Ahrens-Nicklas, Tomoki T. Nomakuchi, and Elizabeth J.K. Bhoj. Coupling deep phenotypic quantification with next-generation phenotyping for 192 individuals with germline histonopathies. Jul 2025. URL: https://doi.org/10.1016/j.xhgg.2025.100440, doi:10.1016/j.xhgg.2025.100440. This article has 5 citations and is from a peer-reviewed journal.

7. (bryant2020histoneh3.3beyond pages 7-8): Laura Bryant, Dong Li, Samuel G. Cox, Dylan Marchione, Evan F. Joiner, Khadija Wilson, Kevin Janssen, Pearl Lee, Michael E. March, Divya Nair, Elliott Sherr, Brieana Fregeau, Klaas J. Wierenga, Alexandrea Wadley, Grazia M. S. Mancini, Nina Powell-Hamilton, Jiddeke van de Kamp, Theresa Grebe, John Dean, Alison Ross, Heather P. Crawford, Zoe Powis, Megan T. Cho, Marcia C. Willing, Linda Manwaring, Rachel Schot, Caroline Nava, Alexandra Afenjar, Davor Lessel, Matias Wagner, Thomas Klopstock, Juliane Winkelmann, Claudia B. Catarino, Kyle Retterer, Jane L. Schuette, Jeffrey W. Innis, Amy Pizzino, Sabine Lüttgen, Jonas Denecke, Tim M. Strom, Kristin G. Monaghan, Zuo-Fei Yuan, Holly Dubbs, Renee Bend, Jennifer A. Lee, Michael J. Lyons, Julia Hoefele, Roman Günthner, Heiko Reutter, Boris Keren, Kelly Radtke, Omar Sherbini, Cameron Mrokse, Katherine L. Helbig, Sylvie Odent, Benjamin Cogne, Sandra Mercier, Stephane Bezieau, Thomas Besnard, Sebastien Kury, Richard Redon, Karit Reinson, Monica H. Wojcik, Katrin Õunap, Pilvi Ilves, A. Micheil Innes, Kristin D. Kernohan, Gregory Costain, M. Stephen Meyn, David Chitayat, Elaine Zackai, Anna Lehman, Hilary Kitson, Martin G. Martin, Julian A. Martinez-Agosto, Stan F. Nelson, Christina G. S. Palmer, Jeanette C. Papp, Neil H. Parker, Janet S. Sinsheimer, Eric Vilain, Jijun Wan, Amanda J. Yoon, Allison Zheng, Elise Brimble, Giovanni Battista Ferrero, Francesca Clementina Radio, Diana Carli, Sabina Barresi, Alfredo Brusco, Marco Tartaglia, Jennifer Muncy Thomas, Luis Umana, Marjan M. Weiss, Garrett Gotway, K. E. Stuurman, Michelle L. Thompson, Kirsty McWalter, Constance T. R. M. Stumpel, Servi J. C. Stevens, Alexander P. A. Stegmann, Kristian Tveten, Arve Vøllo, Trine Prescott, Christina Fagerberg, Lone Walentin Laulund, Martin J. Larsen, Melissa Byler, Robert Roger Lebel, Anna C. Hurst, Joy Dean, Samantha A. Schrier Vergano, Jennifer Norman, Saadet Mercimek-Andrews, Juanita Neira, Margot I. Van Allen, Nicola Longo, Elizabeth Sellars, Raymond J. Louie, Sara S. Cathey, Elly Brokamp, Delphine Heron, Molly Snyder, Adeline Vanderver, Celeste Simon, Xavier de la Cruz, Natália Padilla, J. Gage Crump, Wendy Chung, Benjamin Garcia, Hakon H. Hakonarson, and Elizabeth J. Bhoj. Histone h3.3 beyond cancer: germline mutations in histone 3 family 3a and 3b cause a previously unidentified neurodegenerative disorder in 46 patients. Science Advances, Dec 2020. URL: https://doi.org/10.1126/sciadv.abc9207, doi:10.1126/sciadv.abc9207. This article has 92 citations and is from a highest quality peer-reviewed journal.

8. (bryant2020histoneh3.3beyond pages 2-3): Laura Bryant, Dong Li, Samuel G. Cox, Dylan Marchione, Evan F. Joiner, Khadija Wilson, Kevin Janssen, Pearl Lee, Michael E. March, Divya Nair, Elliott Sherr, Brieana Fregeau, Klaas J. Wierenga, Alexandrea Wadley, Grazia M. S. Mancini, Nina Powell-Hamilton, Jiddeke van de Kamp, Theresa Grebe, John Dean, Alison Ross, Heather P. Crawford, Zoe Powis, Megan T. Cho, Marcia C. Willing, Linda Manwaring, Rachel Schot, Caroline Nava, Alexandra Afenjar, Davor Lessel, Matias Wagner, Thomas Klopstock, Juliane Winkelmann, Claudia B. Catarino, Kyle Retterer, Jane L. Schuette, Jeffrey W. Innis, Amy Pizzino, Sabine Lüttgen, Jonas Denecke, Tim M. Strom, Kristin G. Monaghan, Zuo-Fei Yuan, Holly Dubbs, Renee Bend, Jennifer A. Lee, Michael J. Lyons, Julia Hoefele, Roman Günthner, Heiko Reutter, Boris Keren, Kelly Radtke, Omar Sherbini, Cameron Mrokse, Katherine L. Helbig, Sylvie Odent, Benjamin Cogne, Sandra Mercier, Stephane Bezieau, Thomas Besnard, Sebastien Kury, Richard Redon, Karit Reinson, Monica H. Wojcik, Katrin Õunap, Pilvi Ilves, A. Micheil Innes, Kristin D. Kernohan, Gregory Costain, M. Stephen Meyn, David Chitayat, Elaine Zackai, Anna Lehman, Hilary Kitson, Martin G. Martin, Julian A. Martinez-Agosto, Stan F. Nelson, Christina G. S. Palmer, Jeanette C. Papp, Neil H. Parker, Janet S. Sinsheimer, Eric Vilain, Jijun Wan, Amanda J. Yoon, Allison Zheng, Elise Brimble, Giovanni Battista Ferrero, Francesca Clementina Radio, Diana Carli, Sabina Barresi, Alfredo Brusco, Marco Tartaglia, Jennifer Muncy Thomas, Luis Umana, Marjan M. Weiss, Garrett Gotway, K. E. Stuurman, Michelle L. Thompson, Kirsty McWalter, Constance T. R. M. Stumpel, Servi J. C. Stevens, Alexander P. A. Stegmann, Kristian Tveten, Arve Vøllo, Trine Prescott, Christina Fagerberg, Lone Walentin Laulund, Martin J. Larsen, Melissa Byler, Robert Roger Lebel, Anna C. Hurst, Joy Dean, Samantha A. Schrier Vergano, Jennifer Norman, Saadet Mercimek-Andrews, Juanita Neira, Margot I. Van Allen, Nicola Longo, Elizabeth Sellars, Raymond J. Louie, Sara S. Cathey, Elly Brokamp, Delphine Heron, Molly Snyder, Adeline Vanderver, Celeste Simon, Xavier de la Cruz, Natália Padilla, J. Gage Crump, Wendy Chung, Benjamin Garcia, Hakon H. Hakonarson, and Elizabeth J. Bhoj. Histone h3.3 beyond cancer: germline mutations in histone 3 family 3a and 3b cause a previously unidentified neurodegenerative disorder in 46 patients. Science Advances, Dec 2020. URL: https://doi.org/10.1126/sciadv.abc9207, doi:10.1126/sciadv.abc9207. This article has 92 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00